Astellas Pharma Inc
DUS:YPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Astellas Pharma Inc
DUS:YPH
|
JP |
|
A
|
Ad Pepper Media International NV
XMUN:APM
|
DE |
Intrinsic Value
The intrinsic value of 
Astellas Pharma Inc (YPH) under the Base Case is 13.53 EUR per share.
Compared with the current market price of 14 EUR, the stock appears
Overvalued by 3% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Astellas Pharma Does
Astellas Pharma is a Japanese drug company that discovers, develops, makes, and sells prescription medicines. Its main products treat areas such as urology, transplant medicine, immunology, cancer, and eye disease. The company spends heavily on research and then brings branded drugs through testing, approval, manufacturing, and distribution.
- Headquarters
- Japan JP
- Employees
- 13 643
- IPO date
- May 16, 1949
Astellas Pharma has no economic moat
Patent protection keeps copies of individual Astellas medicines out temporarily, but does not provide lasting protection across the business. Generic competition has reduced Myrbetriq sales, while competing treatments give doctors alternatives to medicines such as Xtandi.
Read the full moat analysis
Revenue & Expenses Breakdown
Astellas Pharma Inc
Earnings Waterfall
Astellas Pharma Inc
The intrinsic value for Astellas Pharma Inc (YPH) under the Base Case is 13.53 EUR.
Compared with the current market price of 14 EUR, the stock appears Overvalued by 3% .
